## Ros Wade

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6542852/publications.pdf

Version: 2024-02-01

623574 552653 27 721 14 26 citations h-index g-index papers 27 27 27 1023 all docs docs citations times ranked citing authors

#	Article	lF	CITATIONS
1	EOS 2D/3D X-ray imaging system: a systematic review and economic evaluation. Health Technology Assessment, 2012, 16, 1-188.	1.3	98
2	QUADAS-C: A Tool for Assessing Risk of Bias in Comparative Diagnostic Accuracy Studies. Annals of Internal Medicine, 2021, 174, 1592-1599.	2.0	88
3	A systematic review of the clinical effectiveness of EOS 2D/3D X-ray imaging system. European Spine Journal, 2013, 22, 296-304.	1.0	83
4	Systematic review and meta-analysis of the value of initial biomarkers in predicting adverse outcome in febrile neutropenic episodes in children and young people with cancer. BMC Medicine, 2012, 10, 6.	2.3	65
5	Systematic review and meta-analysis of the discriminatory performance of risk prediction rules in febrile neutropaenic episodes in children and young people. European Journal of Cancer, 2010, 46, 2950-2964.	1.3	51
6	The EOS 2D/3D X-ray imaging system: A cost-effectiveness analysis quantifying the health benefits from reduced radiation exposure. European Journal of Radiology, 2013, 82, e342-e349.	1.2	49
7	Quality assessment of comparative diagnostic accuracy studies: our experience using a modified version of the QUADASâ€2 tool. Research Synthesis Methods, 2013, 4, 280-286.	4.2	46
8	Systematic review of patient preference and adherence to the correct use of graduated compression stockings to prevent deep vein thrombosis in surgical patients. Journal of Advanced Nursing, 2017, 73, 336-348.	1.5	29
9	Graduated compression stockings for the prevention of deep-vein thrombosis in postoperative surgical patients: a systematic review and economic model with a value of information analysis. Health Technology Assessment, 2015, 19, 1-220.	1.3	26
10	Interventional management of hyperhidrosis in secondary care: a systematic review. British Journal of Dermatology, 2018, 179, 599-608.	1.4	25
11	The Clinical and Cost Effectiveness of Aflibercept in Combination with Irinotecan and Fluorouracil-Based Therapy (FOLFIRI) for the Treatment of Metastatic Colorectal Cancer Which has Progressed Following Prior Oxaliplatin-Based Chemotherapy: a Critique of the Evidence. Pharmacoeconomics, 2015, 33, 457-466.	1.7	21
12	Adjunctive colposcopy technologies for examination of the uterine cervix – DySIS, LuViva Advanced Cervical Scan and Niris Imaging System: a systematic review and economic evaluation. Health Technology Assessment, 2013, 17, i-239.	1.3	20
13	Hyperhidrosis quality of life measures: review and patient perspective. Journal of Dermatological Treatment, 2019, 30, 303-308.	1.1	19
14	Ruxolitinib for the Treatment of Myelofibrosis: A NICE Single Technology Appraisal. Pharmacoeconomics, 2013, 31, 841-852.	1.7	16
15	Patient characteristics as effect modifiers for psoriasis biologic treatment response: an assessment using network meta-analysis subgroups. Systematic Reviews, 2020, 9, 132.	2.5	14
16	Ipilimumab for Previously Untreated Unresectable Malignant Melanoma: A Critique of the Evidence. Pharmacoeconomics, 2015, 33, 1269-1279.	1.7	13
17	Systematic review and metaâ€analysis of the value of clinical features to exclude radiographic pneumonia in febrile neutropenic episodes in children and young people. Journal of Paediatrics and Child Health, 2012, 48, 641-648.	0.4	11
18	Interventions for hyperhidrosis in secondary care: a systematic review and value-of-information analysis. Health Technology Assessment, 2017, 21, 1-280.	1.3	10

#	Article	IF	CITATIONS
19	Thigh length versus knee length antiembolism stockings for the prevention of deep vein thrombosis in postoperative surgical patients; a systematic review and network meta-analysis. BMJ Open, 2016, 6, e009456.	0.8	8
20	Brodalumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal. Pharmacoeconomics, 2019, 37, 131-139.	1.7	7
21	A Review of Ruxolitinib for the Treatment of Myelofibrosis: A Critique of the Evidence. Pharmacoeconomics, 2017, 35, 203-213.	1.7	6
22	The Clinical and Cost Effectiveness of Inotuzumab Ozogamicin for the Treatment of Adult Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal. Pharmacoeconomics, 2019, 37, 1081-1091.	1.7	5
23	Selective internal radiation therapies for unresectable early-, intermediate- or advanced-stage hepatocellular carcinoma: systematic review, network meta-analysis and economic evaluation. Health Technology Assessment, 2020, 24, 1-264.	1.3	4
24	Apremilast for the Treatment of Moderate to Severe Plaque Psoriasis: A Critique of the Evidence. Pharmacoeconomics, 2016, 34, 587-596.	1.7	3
25	Methods for selecting the best evidence to inform a NICE technology appraisal on selective internal radiation therapies for hepatocellular carcinoma. Systematic Reviews, 2020, 9, 184.	2.5	2
26	Characteristics modifying response to biological treatments for psoriasis: considering subgroups in network metaâ€analysis. British Journal of Dermatology, 2021, 184, 358-359.	1.4	1
27	The Cost-Effectiveness of Selective Internal Radiation Therapies Compared With Sorafenib for Treating Advanced Unresectable Hepatocellular Carcinoma in the United Kingdom. Value in Health, 2022, 25, 787-795.	0.1	1